A slightly higher proportion of patients prescribed SGLT2-inhibitors for diabetes understood why they were taking this medication compared with patients prescribed it for heart failure (35% in diabetic patients vs 27% in heart failure patients). The gene discussed is SLC5A2; the disease is heart failure.